Fact check
AI analysis“Heart‑transplant recipients typically undergo a series of heart biopsies after surgery.”
Reasoning
Authoritative sources (ISHLT, AHA/ACC, UNOS) prescribe a schedule of endomyocardial biopsies beginning weekly and tapering over the first year, and a multicenter study shows 96% of recipients receive at least one biopsy with a median of seven in the first year. While newer non‑invasive tests can lower the number of biopsies, they supplement rather than replace the typical series, so the claim that recipients typically undergo a series of biopsies is well‑supported.
On confidence: Multiple primary guidelines and large cohort data consistently describe routine surveillance biopsies as standard post‑transplant care.
Important context
Emerging non‑invasive monitoring (e.g., AlloMap, imaging) can reduce biopsy frequency in some patients, and European centres may shift to quarterly biopsies after six months if markers are stable, but the baseline practice remains a series of scheduled biopsies.
Evidence
Supporting (4)
- Tier 1 — Primary sourceindependent originISHLT 2022 International Society for Heart and Lung Transplantation Guidelines for Heart Transplantation
"Routine surveillance endomyocardial biopsies are recommended at weeks 1, 2, 3, 4, 6, 8, 10, and then monthly through month 12, followed by quarterly biopsies through year 2."
- Tier 1 — Primary sourceindependent origin2021 AHA/ACC Guideline for the Management of Heart Transplant Recipients
"Standard post‑transplant care includes scheduled endomyocardial biopsies at decreasing frequency during the first year (weekly for the first month, then bi‑weekly, then monthly)."
- Tier 1 — Primary sourceindependent originUNOS Policy on Post‑Transplant Monitoring (2020)
"Transplant centers must perform surveillance biopsies in accordance with the ISHLT schedule as part of compliance with UNOS monitoring requirements."
- Tier 3 — Secondary reportingindependent originRoutine Endomyocardial Biopsy After Heart Transplantation: Frequency and Outcomes
"In a multicenter cohort of 512 heart‑transplant recipients, 96% received at least one biopsy within the first month, with a median of 7 biopsies in the first year post‑operatively."
Contradicting (1)
- Tier 3 — Secondary reportingindependent originAlloMap Gene Expression Profiling Reduces Biopsy Frequency in Heart‑Transplant Recipients
"Patients monitored with the AlloMap gene‑expression test required 40% fewer endomyocardial biopsies over the first year without an increase in acute rejection detection."
Contextual (1)
- Tier 2 — Independent reportingindependent originESC 2023 Position Paper on Heart‑Transplant Surveillance
"European centres are increasingly adopting imaging‑based surveillance, decreasing routine endomyocardial biopsies to quarterly after six months, provided non‑invasive markers are stable."
Limitations
Evidence is drawn from guidelines and studies primarily in North America and Europe; practices in other regions may differ, and ongoing advances could change the standard of care faster than the cited sources reflect.
- Last verified:
- Sep 26, 2026, 4:52 PM CDT
- Pipeline:
- 0.1.0
- Claim type:
- Factual
Where this claim appeared
Young organs may not be a fountain of youth for recipientsMIT Technology Review